mardi 7 juillet 2020


InVivo Therapeutics to Present at 34th Annual Symposium of the National Neurotrauma Society

Par Rédaction , dans Communiqués , le 24 juin 2016

Thursday, June 23rd 2016 at 12:00pm UTC

CAMBRIDGE, Mass.–(BUSINESS WIRE)– InVivo Therapeutics Holdings Corp. (NVIV) today announced that
Richard Layer, Ph.D., InVivo’s Senior Director of Research, will be
giving a poster presentation at the National Neurotrauma Society (NNS)
2016 Symposium to be held June 26-29 in Lexington, KY. The abstract,
titled “Biodegradable Neuro-Spinal Scaffold Promotes Neuropermissive
Tissue Remodeling Following Spinal Contusion Injury in Rats” will be
published electronically in the Journal of Neurotrauma immediately
prior to the conference.

“It’s important to continue to raise awareness about our novel approach
to treating spinal cord injuries. We look forward to our participation
in the NNS symposium and to continued outreach to the research
community,” Mark Perrin, InVivo’s Chief Executive Officer and Chairman,
said.

A copy of the abstract will be available after the conference on
InVivo’s website: https://www.invivotherapeutics.com/research-clinical-development/abstracts-and-publications

About The INSPIRE Study

The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal
Scaffold™
for Safety and Neurologic Recovery in Subjects with
Complete Thoracic AIS A Spinal Cord Injury, is designed to demonstrate
the safety and probable benefit of the Neuro-Spinal Scaffold
for the treatment of complete T2-T12/L1 spinal cord injury in support of
a Humanitarian Device Exemption (HDE) application for approval. For more
information, refer to https://clinicaltrials.gov/ct2/show/study/NCT02138110.

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the
biodegradable Neuro-Spinal Scaffold within the decompressed and
debrided injury epicenter is intended to support appositional healing,
thereby reducing post-traumatic cavity formation, sparing white matter,
and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal
Scaffold
, an investigational device, has received a Humanitarian Use
Device (HUD) designation and currently is being evaluated in the INSPIRE
pivotal probable benefit study for the treatment of patients with
complete (AIS A) traumatic acute spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage
biomaterials and biotechnology company with a focus on treatment of
spinal cord injuries. The company was founded in 2005 with proprietary
technology co-invented by Robert Langer, Sc.D., Professor at
Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who
then was at Boston Children’s Hospital and who now is affiliated with
Massachusetts General Hospital. In 2011, the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. In 2015, the
company’s investigational Neuro-Spinal Scaffold received the 2015
Becker’s Healthcare Spine Device Award. The publicly-traded company is
headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Contacts

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor
Relations
bluque@invivotherapeutics.com

Source: InVivo Therapeutics Holdings Corp.

Étiquettes : , , , , , , , , ,